Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on aTyr Pharma (NASDAQ: ATYR).The analyst commented, "aTyr’s Efzofitimod (NRP2 modulator) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE